💬In plain words
What the trial is, and whether it could suit you
Opioid use disorder (OUD) is a chronic relapsing disorder and is well-known for its high-risk rate of overdoses and death. In OUD, sleep and circadian disruptions are highly prevalent, interfere with opioid maintenance treatment outcomes and increase the risk of relapse. So far, commonly used pharmacological sleep treatments fail to improve sleep or decrease illicit drug use in OUD. Thus, there is an urgent need to fill this research gap.
Previous work showed that OUD patients who were receiving opioid agonist treatment (MOUD+) exhibited greater irregularity of sleep-wake cycle. In OUD patients, sleep-wake irregularity was associated with years of heroin use and low light exposure. Bright light therapy (BLT) is a very promising circadian/sleep intervention for several sleep, psychiatric and neurological disorders. BLT improved circadian, sleep outcomes and negative mood. In a pilot stud
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* All Participants
* Between 18 and 60 years old
* Fluent in English
* Able to provide written informed consent
OUD
* DSM-5 diagnosis of an OUD.
* ≥12 months of lifetime opioid use
* Positive on urine drug screen for buprenorphine or methadone
* Receiving opioid agonist therapy for OUD (e.g., methadone or buprenorphine) with a stable dose for the past month. Must have been stabilized on OMT medication, since the increasing of doses during induction phase might interfere with outcomes and unstable patients might experience strong withdrawal symptoms in the morning which makes them unsuitable for a home-based BLT.
* Other substance use was not exclusionary, but opioids were identified as primary.
Exclusion Criteria:
All Participants
* Head trauma with loss of consciousness for more than 30 minutes as determined by medical history.
* history of seizures/epilepsy.
* Pregnant and/or currently breast-feeding.
* Presence of ferromagnetic objects in the body that are contraindicated for MRI or fear of enclosed spaces.
* Eye disease including disease of the anterior and posterior segment of the eye, cataracts, retinopathy, glaucoma, amblyopia, scotoma, color or night blindness, corneal pathologies, macular degeneration, or retinitis pigmentosa reported by history or identified by eye exam
* History of eye surgery
* Chronic migraine triggered by bright light
* worked night shift or traveled across\>2 time zones in the past month
OUD
* diagnosis of substance use disorder other than for opioids that was deemed to be primary
* lifetime diagnosis of schizophrenia, bipolar disorder, or suicidality.
* History of light treatment
* Unstable dose of psychiatric medication (hypnotics, sleep aids, and antidepressants must be stable for 30 days before and during the study)
HC
* Current or past DSM-IV or DSM-5 diagnosis of a psychiatric disorder including substance use disorder (except for nicotine/caffeine).
* Current DSM-5 sleep-wake disorders including insomnia disorder
💊
What it tests
- AYO light glasses (experimental)
- AYO light glasses (comparator)
University of Alabama at Birmingham
Birmingham, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky